Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT05983848 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Scintigraphy for Prediction In Rheumatoid Intentional Therapy Tapering

SPIRITT
Start date: October 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to investigate whether 99mTc-maraciclatide imaging prior to biologic therapy tapering and after 3 months can predict those at risk of Rheumatoid arthritis flare. Participants undergoing routine tapering of biologic drug therapy will have 99mTc-maraciclatide imaging in addition to normal ultrasound imaging and then followed up over 12 months to assess whether an interval scan alone or in combination with the baseline scan is predictive of flare.

NCT ID: NCT05973370 Completed - Clinical trials for Rheumatoid Arthritis

Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the potential therapeutic effects of the secondary bile acid ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered as add-on treatments to the current DMARDs treatment for rheumatoid arthritis patients with variant disease activity.

NCT ID: NCT05972603 Recruiting - Clinical trials for Rheumatoid Arthritis

Role of Topical Vancomycin in Reducing Infections in Hip and Knee Arthroplasty

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The study is designed to assess the efficacy of vancomycin powder and dilute povidone-iodine lavage (VIP protocol) in reducing the PJI after primary Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA). We hypothesized that VIP protocol provides superior reduction of periprosthetic joint infection (PJI) rates after primary THA and TKA compared with diluted povidone-iodine (PI) protocol.

NCT ID: NCT05966519 Recruiting - Clinical trials for Rheumatoid Arthritis

ROSA Knee Intraoperative Planning Flexibility Study

IntraOP
Start date: January 5, 2024
Phase:
Study type: Observational

The purpose of this study is to verify that an orthopedic surgical assist robot (ROSA Knee System) can provide intraoperative adjustment of osteotomy angle and volume for total knee arthroplasty (TKA) based on feedbacks obtained from intraoperative soft tissue conditions. A total 80 cases will be enrolled at one study site with a postoperative follow-up period of 2 years.

NCT ID: NCT05957770 Completed - Clinical trials for Rheumatoid Arthritis

Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Rheumatoid Arthritis Patients

Start date: February 1, 2023
Phase:
Study type: Observational

The goal of this case control observational study is to asses anxiety, sleep, depression and quality of life in rheumatoid arthritis patients The main aims are: - asses anxiety, sleep, depression and quality of life in rheumatoid arthritis patients - their relation to disease activity we will compare rheumatoid arthritis patients to healthy subjects.

NCT ID: NCT05957107 Completed - Clinical trials for Rheumatoid Arthritis

Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

Start date: May 26, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic characteristics, and immunogenicity of VDJ001 in RA patients.

NCT ID: NCT05955066 Recruiting - Clinical trials for Rheumatoid Arthritis

Effect of JAK Inhibitor on Erosion Healing in RA

Start date: December 1, 2023
Phase: Phase 4
Study type: Interventional

Objective To investigate the effect of Janus kinase (JAK) inhibition by baricitinib on erosion healing in rheumatoid arthritis (RA) patients with active disease using high-resolution peripheral quantitative computer tomography(HR-pQCT). Hypothesis JAK inhibitor can lead to healing of existing erosion in RA patients with active disease. Design and subjects This is a 24-week, randomized, placebo-controlled, double-blind study. We plan to enroll 60 adult patients with active RA (Disease activity score 28-C-reactive protein [DAS28-CRP]>3.2) and 1 bone erosion on HR-pQCT. They will be randomized 1:1 to receive JAK inhibitor (baricitinib 4mg once daily) or placebo for 24 weeks. Medications will be adjusted according to a standard protocol aiming to achieve low disease activity. Patients requiring biologic or other targeted synthetic disease-modifying-anti-rheumatic-drugs will be excluded. Study instruments HR-pQCT of the 2-4 metacarpophalangeal(MCP) will be done at baseline and 24 weeks. Inflammatory cytokine profile and bone cartilage interface biomarkers will also be checked at baseline and 24 weeks. Clinical response will be monitored using DAS28-CRP. Main outcome measures and analysis The primary outcome is the proportion of patients with erosion volume regression on HR-pQCT comparing the two groups by chisquare test.

NCT ID: NCT05952440 Recruiting - Clinical trials for Rheumatoid Arthritis

Dissecting the Cellular and Molecular Atlas of Rheumatoid Arthritis in Sustained Remission to Identify Pathways Maintaining Remission and Triggering Flares

FLARE-RA
Start date: July 11, 2023
Phase:
Study type: Observational

The FLARE-RA study will have the following research objectives: A) To establish the cellular and molecular atlas of remission RA achieved with different therapeutics aimed to identify (i) cell clusters/pathways driving disease flare or maintaining remission and (ii) provide an evidence base for developing ML tools for predicting flares. B) To test the performance of a ML-derived algorithm on longitudinal remission RA cohort in a biopsy-driven study. C) To dissect the cellular and molecular mechanisms of remission maintenance and joint flares.

NCT ID: NCT05944198 Recruiting - Clinical trials for Rheumatoid Arthritis

Clinical Study of 18F-FAPI-RGD PET/CT in Rheumatoid Arthritis

Start date: July 14, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about 18F-FAPI-RGD PET/CT imaging in assessing rheumatoid arthritis disease activity. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

NCT ID: NCT05942976 Completed - Clinical trials for Rheumatoid Arthritis

Enthesis Differences in Rheumatoid Arthritis and Axial Spondyloarthropathy

Start date: June 16, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to investigate the sonographic differences in entheses in patients with Rheumatoid arthritis and Axial Spondyloarthropathy.